abs

학술발표회초록보기

Inquiry on Abstract abstract@kcsnet.or.kr

Inquiry on Payment member@kcsnet.or.kr

130th General Meeting of Korean Chemical Society Development of Ticagrelor formulation of sustained release with Eudragit RS/RL by solid dispersion

Submission Date :
8 / 4 / 2022 , 17 : 44 : 14
Abstract Number :
130080401318
Presenting Type:
Poster Presentation
Presenting Area :
Industrial Chemistry
Authors :
Seung Jae Kim, Youngjun Son, Se Eun Kim, Jinsol Seo, Taewoong Kang, Jeong Eun Song, Gilson Khang1,*
Bionanotechnology and Bio-Convergence Engineering, Jeonbuk National University, Korea
1PolymerNano Science & Technology and Polymer Materials Fusion Research Center, Jeonbuk National University, Korea
Assigned Code :
TBA
Presenting Time :
TBA
Ticagrelor is a drug belonging to the biopharmaceutical classification system IV (BCS class IV) with low permeability and solubility as a drug to suppress the heart attack and apoplexy in patients undergoing acute coronary syndrome (ACS) in advance. In order for patients to take the efficacy of this drug, the process of increasing bioavailability is essential, and for this, the process of drug solubilization is inevitable. To this end, this study used the spray drying method, that is the most common and simple solid dispersion method, and Eudragit RLPO and Eudragit RSPO which are the pH-independent and hydrophilic polymers were used as drug carriers. Differential scanning calorimetry (DSC) and X-ray diffractometer (XRD) was used to confirm that the Ticagrelor was dispersed in polymer as an amorphous form, and Fourier transform infrared spectroscopy (FTIR) was used to confirm the chemical change. Finally, it was possible to confirm that the release of the drug was controlled by performing the dissolution test, and it was able to design a formulation that improved the burden of the patient's drug dose by reducing the number of daily administration. Therefore, we present a new formulation suitable for the treatment of patients with acute coronary syndrome (ACS). This work was supported by the material, parts technology development project (package type) (20013651, Development of an aseptic sterilizer for producing biopharmaceuticals by control pressure 0.01Mpa 1.0 precision based on AL Fuzzy) funded by the Ministry of Trade, industry & Energy (MOTIE, Korea).